TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07617597: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Sponsor: Sun Pharma Japan Limited · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 78 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,253,928

Rescue Site Savings

+$4,799,316

Unlock Full NCT07617597 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07617597 Rescue Dossier →